Drug Profile
Research programme: cell cycle regulation - Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Pfizer
- Class Piperazines; Pyridines; Pyridones; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 19 Jan 2009 Preclinical development in cancer is still ongoing in the US
- 01 Mar 2005 Syrrx has been acquired by Takeda